Bausch Health (NYSE:BHC) Q4 2025 Earnings call February 18, 2026 05:00 PM ET Company ParticipantsGaren Sarafian - VP and Head of Investor RelationsGlen Santangelo - Managing DirectorJJ Charhon - EVP and CFOJonathan Sadeh - CMO and Head of Research and DevelopmentLes Sulewski - VP of Spec Pharma and Biotech Equity ResearchThomas Appio - CEOUmer Raffat - Equity Research of Biotech, Pharma-major, and Specialty PharmaConference Call ParticipantsMichael Freeman - Equity Research AnalystNone - AnalystNone - Analy ...

Financial Data and Key Metrics Changes - Bausch Health reported a revenue increase of 9% in Q4 2025 compared to Q4 2024, reaching $2,796 million, with adjusted EBITDA rising by 13% to $1,052 million [10][11] - For the full year 2025, revenue grew by 7% and adjusted EBITDA by 10%, indicating strong operational performance [18][19] - Adjusted gross margin was 71.6%, down 80 basis points year-over-year, while adjusted operating expenses increased by $75 million to $1,033 million [10][11] Business Line Data and Key Metrics Changes - Salix revenue in Q4 was $693 million, a 9% increase year-over-year, driven by strong demand and promotional efforts [12] - Solta Medical segment revenues decreased by 1% to $137 million, impacted by distributor transition in China, but would have shown mid-single-digit growth without this effect [15][16] - The diversified segment saw a 12% revenue increase to $255 million, primarily due to improved net pricing [16] Market Data and Key Metrics Changes - International segment revenues were $306 million, up 10% on a reported basis, with EMEA and LatAm showing double-digit growth, while Canada contracted by 6% [13][14] - The Latin American market returned to growth with a 22% revenue increase, while Canada faced challenges due to increased generic competition [14][15] Company Strategy and Development Direction - The company aims to enhance operational assets through innovation and optimize brand growth globally, with a focus on business development opportunities [21][22] - The acquisition of Shibo's aesthetics distribution platform in China is expected to strengthen the company's market presence and enhance direct engagement with providers [7][26] - Strategic priorities for 2026 include maximizing shareholder value and optimizing the capital structure following significant refinancing [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong cash generation and improved capital structure, allowing for proactive business development [5][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance range of $5.25 billion to $5.4 billion [20][21] - Management acknowledged the disappointment regarding the RED-C trial results but remains focused on advancing other development opportunities [9] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow for the year and reduced net debt by approximately $320 million in Q4 [7][12] - The debt maturity profile was improved by approximately $1.7 billion through a debt exchange, providing additional flexibility for future opportunities [7][19] Q&A Session Summary Question: Post RED-C readout, what is the updated decision framework for separation and debt repayments? - Management stated there is no change in focus, continuing to prioritize debt repayment and reinvestment in the business [33] Question: Can you provide more details about business development plans? - Management is screening various assets for potential acquisitions, leveraging their strong commercial team [36][37] Question: What is the impact of the Shibo integration on revenue and EBITDA growth? - The integration is progressing well, with a minor EBITDA impact of $10-$15 million due to accounting adjustments [45][47] Question: What are the expectations for Xifaxan generics? - Management confirmed that a generic is expected by January 1, 2028, and is focused on maximizing current value [84] Question: What is the EBITDA trajectory for 2027? - Management indicated that 2027 EBITDA would likely be around $2.7 billion, reflecting a dip compared to 2025 [86]

Core Viewpoint - PAVmed has successfully closed financings that eliminate all previously outstanding convertible securities, significantly strengthening its balance sheet and capital structure [1] Financing Details - The Series D Preferred Stock offering generated $30 million in gross proceeds, with warrants for an additional $30 million contingent on a positive Medicare local coverage determination for the EsoGuard test [1] - A new senior secured note with a three-year maturity raised an additional $15 million [1] - The total net cash proceeds from these transactions amount to approximately $7.7 million, which will be used for general working capital [1] Capital Structure Improvement - The proceeds from the financings were utilized to redeem all outstanding Series C Convertible Preferred Stock and fully retire existing convertible debt [1] - Assuming the exercise of associated warrants and conversion of Series D Preferred Stock, the company could achieve a clean capital structure consisting entirely of common stock and long-term debt, adding approximately $37.7 million in cash to the balance sheet [1] Strategic Positioning - PAVmed's Chairman and CEO highlighted that this transaction is a transformative outcome aimed at fixing the legacy capital structure and unlocking the company's asset strength for shareholders [1] - The company is now positioned to pursue additional commercial opportunities and enhance long-term shareholder value, leveraging its subsidiaries, including Lucid Diagnostics and Veris Health [1]

Core Viewpoint - Saudi Aramco has successfully completed a $4 billion bond issuance, demonstrating its ability to raise capital under favorable conditions despite global market volatility [1]. Group 1: Bond Issuance Details - The bond sale was structured into four tranches: $500 million in senior notes maturing in 2029 with a 4.0% coupon, $1.5 billion in 2031 notes at 4.375%, $1.25 billion in 2036 notes at 5.0%, and $750 million in long-dated 2056 notes with a 6.0% coupon [2]. - The transaction was priced on January 26 and the notes were listed on the London Stock Exchange [2]. Group 2: Investor Confidence and Pricing - Pricing included negative new issue premiums on three of the four tranches, indicating strong investor confidence in Aramco's balance sheet and credit profile [3]. - Such pricing is typically reserved for top-tier issuers, reflecting Aramco's status as one of the strongest credits in the global energy sector [3]. Group 3: Strategic Financial Management - The issuance aligns with Aramco's strategy to optimize its capital structure while maintaining strict financial discipline, supporting long-term shareholder value creation [4]. - Accessing long-dated capital at competitive rates provides financial flexibility for Aramco while preserving cash flows for dividends and strategic projects [5]. Group 4: Market Position and Historical Context - Aramco has been a regular issuer in international debt markets since its debut global bond sale in 2019, primarily using proceeds for general corporate purposes and balance sheet management [6]. - The company benefits from substantial hydrocarbon reserves, low production costs, and strong ties to the Saudi state, which support its robust credit metrics [6]. Group 5: Investor Demand and Market Trends - The successful bond placement signals ongoing investor demand for high-quality energy credits, despite energy transition risks and oil price volatility [7]. - For sovereign-linked producers with scale and financial strength, debt markets remain an attractive tool for capital management [7].

Core Insights - BV Financial, Inc. reported a significant increase in net income for the fourth quarter of 2025, reaching 56 cents per share compared to 18 cents per share in the same period last year [1] - The company's stock has seen a decline of 2% since the earnings report, contrasting with a 0.9% increase in the S&P 500 index during the same timeframe [1] Financial Performance - Net income more than doubled year-over-year to $4.8 million from $2 million, with non-GAAP adjusted net income rising to $5.6 million from $2.4 million [2] - Full-year net income was reported at $13.5 million, or $1.43 per share, up from $11.7 million, or $1.10 per share in 2024 [2] - Adjusted net income grew to $16.3 million from $12.9 million, reflecting adjustments for expenses related to the 2024 Equity Incentive Plan [2] Key Business Metrics - Total assets as of December 31, 2025, were $912.2 million, a slight increase from $911.8 million the previous year [3] - Net loans increased by $19.2 million, or 2.6%, to $748.5 million, with growth in specific loan categories offsetting declines in others [3] Deposits and Debt Management - Total deposits rose by $24.6 million, or 3.8%, to $676.1 million, driven by a 6.7% increase in non-interest-bearing deposits [4] - The company repaid $35 million in subordinated debt, replacing it with lower-cost Federal Home Loan Bank advances [4] Shareholder Value Initiatives - BV Financial executed a stock buyback program, repurchasing 1.8 million shares during 2025 at an average price of $16.23, including 714,555 shares in the fourth quarter [4] Efficiency and Returns - Return on average assets (ROAA) improved to 2.1% from 0.9% year-over-year, while return on average equity (ROAE) surged to 10.5% from 3.8% [5] - The efficiency ratio improved to 51% in the fourth quarter from 64.3% in the prior-year period, indicating stronger operating leverage [5] Strategic Management Decisions - The company's strategic focus includes optimizing its capital structure and cost management, as evidenced by the replacement of subordinated debt and the share repurchase program [6] Earnings Drivers - A key contributor to the earnings upside was a $1.9 million recovery in provision for credit losses in the fourth quarter, reversing a provision of $0.6 million in the year-ago period [7] - Net interest income rose 8.2% year-over-year in the quarter to $9.8 million, driven by a higher net interest margin of 4.52%, up from 4.34% [8] Noninterest Income and Expenses - Noninterest income saw a modest increase to $0.8 million in the quarter from $0.6 million a year earlier [9] - Noninterest expense declined 13.4% year-over-year to $5.4 million, largely due to a drop in compensation and benefits expenses [9] Balance Sheet Maneuvers - The company retired its $35 million subordinated debt issued in 2020, replacing it with lower-cost Federal Home Loan Bank borrowings, expected to reduce interest expense going forward [10]

Core Viewpoint - Trinity Biotech plc has entered into agreements with Perceptive Advisors to enhance its financial flexibility and optimize its capital structure, supporting ongoing and future growth projects [1][2]. Financial Capacity and Operational Flexibility - The transactions strengthen Trinity Biotech's financial capacity and operational flexibility, enabling continued investment in strategic growth priorities and reinforcing its ability to deliver advanced diagnostic and diabetes management solutions [2][3]. - The agreements position Trinity Biotech to advance its long-term growth agenda while supporting a reduction in overall debt levels [2]. Overview of the Transactions - The agreements reflect a positive relationship between Trinity Biotech and Perceptive Advisors, underscoring their support for the Company's strategy and operational momentum [3]. Financial Summary - The Second Amendment to the Credit Agreement extends the maturity to early 2027 and provides increased near-term funding [6]. - New term-loan proceeds of $5 million will strengthen liquidity for key strategic development initiatives, including the continuous glucose monitoring solution, CGM+ [7]. - Up to $60 million in elective equitization capacity under the term-loan may allow for significant debt and cash interest cost reductions [7]. - Equity settlement mechanisms for milestone payments and contingent obligations are designed to reduce cash requirements [7]. Management Commentary - The CEO of Trinity Biotech stated that these developments place the company in a stronger strategic position to accelerate its innovation agenda, particularly in diabetes management and diagnostics [8].

Core Viewpoint - Nuvini Group Limited has successfully renegotiated earnout contingent liabilities with founders of previously acquired companies, resulting in a 36% reduction in these obligations, which significantly improves its capital structure and debt profile [1][2]. Capital Structure Improvement - The restructuring enhances Nuvini's proforma debt-to-EBITDA ratio, positioning the company to secure more favorable terms for private credit financing [2]. - This improved capital structure will facilitate the payoff of existing obligations and fund new strategic acquisitions within the next 90 days [2]. Strategic Rationale - The restructuring reflects the company's commitment to maintaining a disciplined and optimized capital structure while executing its acquisition strategy [3]. - By renegotiating earnout obligations, Nuvini has created significant financial flexibility, enabling access to private credit markets on more attractive terms [3]. - The renegotiation highlights the strong relationships Nuvini maintains with founders across its portfolio, aligning all parties on long-term value creation opportunities [3]. M&A Pipeline Update - Nuvini is advancing its strategic acquisition agenda and is on track to close the acquisition of MK Solutions, a leading ERP for ISPs [4]. - The company has a robust pipeline of negotiated acquisition targets that meet its disciplined investment criteria [4]. Future Growth Strategy - The company believes it is prudent to optimize its capital structure before pursuing additional transactions, which positions it to execute more efficiently and on better terms as it aims for growth objectives [5].

Core Viewpoint - Green Rain Energy Holdings, Inc. is implementing strategic corporate actions to enhance its capital structure, improve transparency, and position itself for disciplined growth and long-term shareholder value creation [1]. Share Cancellation and Authorized Share Reduction - The company has requested the cancellation of 310,000,000 shares of common stock held by Maddy's Legacy LLC, controlled by CEO Alfredo Papadakis [1]. - Green Rain is also reducing its authorized common shares to 1.5 billion [2]. Strategic Rationale for Share Actions - The reduction of outstanding and authorized shares addresses dilution concerns and is expected to improve market perception, lower long-term dilution risk, align management and shareholders, and provide greater flexibility for future financings [3]. Regulation A Requalification and Debt Optimization - Green Rain is working to re-qualify its Regulation A offering, intending to use Reg A shares to settle existing debt obligations, thereby reducing balance-sheet pressure without excessive dilution [4]. - The fixed share price for Reg A is planned to be adjusted from $0.0055 to $0.015 per share [4]. Strategic Rationale for Regulation A Requalification - Requalifying Reg A at a higher price reflects improved corporate governance and a disciplined capital strategy, which helps improve solvency ratios and preserves capital for operations and growth [5]. Independent Audit Engagement - Green Rain has engaged Barton CPA to conduct audits of its financial statements for December 31, 2025, and December 31, 2024 [6]. - Independent audits are expected to enhance investor confidence, improve access to capital, and strengthen regulatory compliance [7]. Positioning for the Future - The coordinated actions aim to transition Green Rain into a financially disciplined and investor-aligned company, laying the groundwork for sustainable growth in EV infrastructure and clean energy initiatives [8].

Core Insights - SCHMID Group N.V. has secured a two-tranche term loan facility of up to €10 million to strengthen its financial structure and working capital [1][2] - The first tranche of €2.5 million is expected to be drawn on December 18, 2025, with the second tranche anticipated in early 2026 [2] - The company appointed Arthur Schuetz as the new Chief Financial Officer, effective January 1, 2026, bringing over 20 years of investment banking experience [3][4] Financial Structure - The term loan includes an optional equity conversion right at a fixed share price of USD 2.15 per share [1] - A related party loan raised an additional €200,000, involving the company's Chairman, Board members, and external investors [1] - The financing aims to convert strong order intake into revenues and optimize the company's capital structure for future opportunities [2] Leadership Changes - Arthur Schuetz will replace Julia Natterer as CFO, who will focus on daily operations at Gebr. Schmid GmbH [3] - Schuetz's background includes leading equity and debt capital fundraisings and managing complex cross-border M&A transactions [3][4] - The board expresses confidence in Schuetz's ability to enhance the company's financial strategy and stakeholder value [4] Company Overview - SCHMID Group is a global leader in high-tech electronics, photovoltaics, glass, and energy systems, headquartered in Freudenstadt, Germany [7] - The company employs over 800 staff and operates technology centers and manufacturing sites in Germany and China [7] - It focuses on customized equipment and process solutions, ensuring high technology levels and sustainability in production processes [7]

Core Viewpoint - Green Rain Energy Holdings Inc. is taking strategic action to strengthen its capital structure by canceling 310 million common shares held by CEO Alfredo Papadakis in exchange for restricted preferred shares, aimed at combating short positions in the market [1][2][3]. Group 1: Share Structure Changes - The cancellation of 310 million common shares will significantly reduce the Company's outstanding common share count, reinforcing management's commitment to protecting shareholder value and ensuring long-term stability [2]. - By converting his holdings into restricted preferred shares, the CEO aligns his interests with those of long-term investors while limiting the availability of common shares for short selling [2][3]. Group 2: Management's Commitment - The decision reflects the Company's dedication to building shareholder confidence and protecting its integrity, with expectations that it will stabilize trading activity and reduce volatility caused by short positions [3]. - The restricted preferred shares will have limitations on transferability and conversion, ensuring a disciplined capital structure aligned with strategic objectives [3]. Group 3: Company Focus - Green Rain Energy Holdings remains focused on advancing its energy initiatives and delivering value to shareholders through responsible governance, innovation, and transparency [4].